ARTICLE | Clinical News

Repligen data

August 9, 1993 7:00 AM UTC

RGEN said that AM285, a small molecule developed by its Amira Inc. subsidiary, has shown the ability to inhibit solid tumor growth in nude mice implanted with human cervical carcinoma cells. The compound modulates energy flow through the enzyme creatine kinase (CK). CK is an energy buffering system present in tissues of high energy demand, such as the brain, heart and skeletal muscle. Mice were implanted with tumor cells and began treatment on the same day. In animals fed 1 percent dietary AM285, tumors grew on average to 149 mm3. Tumors of untreated animals grew to 506 mm3. The drug had no effect on normal cells. ...